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Abstract 
This paper analyses the impact of sugar availability/intake on diabetes expenditure and 
on total health care expenditure. Building this macroeconomic analysis upon the literature on 
the determinants of health care expenditure, we estimate a dynamic panel data model over a 
sample of 156 countries for the period 1995-2014. After controlling for the traditional 
determinants of health care spending, we find that an increase in sugar availability/intake leads 
to a significant rise in diabetes expenditure (per capita and per diabetic) and in the growth rate 
of total health care expenditure per capita. Moreover, we show that this causal relation is 
present in both developed and developing countries. 
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1. Introduction 
In the 1960s, John Yudkin, a British physiologist and nutritionist, called the attention to the 
negative impact of sugar consumption on health. According to his studies, the rise in the 
consumption of sugar was leading to an increase in the incidence of diseases, like coronary 
thrombosis, dental caries, obesity, diabetes, liver disease, dyspepsia and some cancers. His book 
“Pure, White and Deadly” summarizes very eloquently the damages caused by sugar on health and 
the respective costs for society (Yudkin, 1988). His message was not very welcome by the sugar 
industry and by the manufacturers of processed foods, who have been accused of using large 
quantities of sugar in their products. They discredited Yudkin's work and impeded it from being 
widespread. Only in the beginning of this decade, Robert Lustig, a pediatric endocrinologist of the 
University of California, brought the sugar again to the centre of the discussion. 
Robert Lustig‟s research shows that sugar overconsumption has serious negative effects on 
health, in particular, and on the society, in general. The long-term economic, health care and human 
costs are considerable. For example, “The United States spends $65 billion in lost productivity and 
$150 billion on health-care resources annually for morbidities associated with metabolic syndrome. 
Seventy-five per cent of all US health care dollars are now spent on treating these diseases and 
their resultant disabilities.” (Lustig et al., 2012, p. 28). More recently, the Morgan Stanley Research 
issued a report that states that “where estimates of total costs exist, these range between 1%-2% of 
a country‟s GDP.” (Morgan Stanley, 2015, p. 16). The report also emphasizes the indirect costs of 
sugar overconsumption to economy: increased mortality, reduced workforce, loss of productivity 
and, ultimately, a decline in economic growth. 
In an empirical analysis for a panel of 175 countries over the period 2000-2010, Basu et al. 
(2013) unveil the presence of a strong relationship between the incidence of diabetes and sugar 
availability. The authors investigated whether the availability of other food groups including, oils, 
meats, cereals, fruits and fibers – as well as socioeconomic factors such as income, urbanization 
and aging – were related to diabetes prevalence, but they only found statistically significant 
evidence of a sugar-diabetes link. 
In our study, we move a step forward and analyse whether the increase in sugar 
availability/intake is causing health care expenditure to rise. We start by looking at the impact of 
sugar intake on diabetes expenditure – given the proven significant relation between sugar and the 
prevalence of this disease (Basu et al., 2013) – and then we evaluate its impact on total health care 
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expenditure. One important argument in favour of the study of this relation is the alarming fact that 
75% of the health care expenditure in the US is concerned to diseases or health conditions related 
to sugar overconsumption (Lustig et al, 2012). The Credit Swiss Research Institute highlights that 
“The future costs of dealing with all these diseases are putting further pressure on the private and 
public sectors‟ finances alike.” (Credit Swiss, 2013, p. 4). Moreover, the International Diabetes 
Federation (IDF) estimates that by the end of 2015 “diabetes will have caused 5.0 million deaths 
and have cost between USD 673 billion and USD 1197 billion in healthcare spending. If this rise is 
not halted, by 2040 there will be 642 million people living with the disease.” (IDF, 2015, p. 9). 
This report also mentions some figures for 2040 spending with diabetes, which “is projected to 
exceed USD 802 billion to USD 1452 billion in today‟s dollars.” (IDF, 2015, p. 58). In a 
descriptive study for five European Union countries, Kanavos et al. (2012) calls the attention to the 
indirect costs of diabetes (reduced productivity, absenteeism, early retirement, social benefits and 
career costs) and its complications, which are likely to be underestimated. They state that the 
indirect costs “can exceed direct costs by at least a factor of 2 – or even 3 – to 1, depending on the 
country.” (Kanavos et al. 2012, p. 1). Hence, many arguments are put forward to the need of a 
cause-effect study on the health care costs of sugar consumption. 
To proceed with this study, we build our analysis upon the standard literature on the 
determinants of health care expenditure and estimate a dynamic panel data model over a sample of 
156 countries for the period 1995-2014. Accounting for the traditional determinants of health care 
expenditure – income, population structure, medical/technological progress, urbanization, female 
participation in the labor force, share of public health expenditure, hospital beds, air pollution, 
among others – we find that an increase in sugar availability leads to a significant rise in diabetes 
expenditure (per capita and per diabetic) and in the growth rate of total health care expenditure per 
capita. This trend is observed in both developed and developing countries. 
The paper is organized as follows. Section 2 presents a review of the literature. Section 3 
describes the data and presents the econometric model. The main results are presented and 
discussed in section 4. Section 5 concludes. 
 
2. Review of the literature 
The seminal work of Newhouse (1977) has set the agenda to the analysis of the 
determinants of health care expenditure. His study identified income as the main cause of 
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healthcare expenditure in 13 OECD countries. Other subsequent studies, also with cross-sectional 
data for OECD countries, confirmed this result (Leu 1986; Parkin et al., 1987; Gerdtham et al., 
1992; among others). An important issue considered in this (so-called) first generation of studies on 
the determinants of health care expenditure was the question of whether health care is a luxury or a 
normal good, i.e. whether a larger than proportionate increase in income (GDP per capita) is spent 
on health care or not. Most of the first generation studies find income elasticity higher than one, 
concluding that health is a luxury good. 
Despite some studies start to consider other variables, like the share of population below 15 
and above 64 years, share of urban population, share of public health expenditure, ratio of female 
participation in the labor force, they relied only on cross-section data, which means that they could 
not control for individual country differences. Moreover, the econometric models employed in 
those studies were very basic and the absence of some variables may have led to a specification 
bias of omitted variables generating large income elasticities. 
However, in the 1990s emerges a second-generation of studies that rely on the use of time 
series and panel data. They start to find income elasticities close to one, implying that health is a 
normal good (Culyer, 1990; Hitiris and Posnett, 1992). Panel data also allows an increase in the 
size of the sample and the control for specific country and time effects. At the same time, a wide 
range of variables that vary over time are considered and more papers analyse the impact of 
population ageing, urbanization, share of public financing to total health expenditure, and female 
participation in the labor force on health care spending. Despite most of these variables are found 
to be relevant (see, for example, Gerdtham et al. (1992); Hitiris and Posnett (1992); and Barros, 
1998), no consensus was reached regarding the importance of population aging.1 
The stationarity of the series became an important issue. Hansen and King (1996) consider 
inadequate the studies by Culyer (1990) and Hitiris and Posnett (1992), because the time series 
they use are not stationary. Thus, the use of time-series data call the attention to the issue of non-
stationarity – which implies that conventional hypothesis testing procedures based on the critical 
values of the tests are not valid. These concerns led some authors to develop approaches that take 
into account the non-stationarity of the series and to implement panel unit root and cointegration 
                                                             
1 While Blomqvist and Carter (1997) show that population ageing is associated with per capita higher health care 
expenditure, Getzen (1992) and Barros (1998) do not find evidence to support that hypothesis for a panel of 
OECD countries. Zweifel et al. (1999) reach the same result but using longitudinal individual data collected from 
a Swiss health insurer instead of macroeconomic data as the other studies. 
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tests. This constitutes the so-called third generation of studies on the determinants of health care 
expenditure. They end up finding that health care income elasticities are less than unity and, in 
some cases, no long-run relationship between health care expenditure and income is found (see 
Hansen and King, 1996; and Blomqvist and Carter, 1997). Nevertheless, the controversy on 
whether the series used are non-stationary or not, in the first place, remains.2 
The discussion proceeds over this millennium, with several studies confirming that per 
capita income remains as the main determinant of per capita health care expenditure and that it is 
more a necessity rather than a luxury (Giannoni and Hitiris, 2002; Baltagi and Moscone, 2010; 
Colombier, 2012; and Hosoya, 2014). Population aging has also assumed some relevance 
(Herwartz and Theilen, 2010; Christiansen et al., 2006; and Hosoya, 2014). 
Despite the relevance of the urbanization, the role of both the share of public financing to 
total health expenditure and the female participation in the labor force has been reinforced in some 
recent studies. Other variables have also been added to the analysis, like medical and technological 
progress, usually controlled with the inclusion of a time-trend variable,3 and supply side variables. 
For example, in studies for European countries, OECD countries, and US states, respectively, 
Christiansen et al. (2006), Mosca (2007) and Wang (2009) call the attention to the importance of 
the number of physicians, hospital beds, diagnostic and treatment technologies, and the 
centralization/decentralization of health care system.4 
This paper extends the literature on the determinants of health care expenditure in several 
directions. First, the studies on this topic are essentially implemented over panels of OECD 
countries or individual (developed) countries, and very little attention has been given to the world-
                                                             
2 While McCoskey and Selden (1998) reject the null hypothesis of unit roots for health care expenditure and GDP, 
Roberts (1999) finds both variables to be non-stationary. Gerdtham and Lothgren (2000), using panel 
cointegration tests over 21 OECD countries, show that both have a unit root but they are cointegrated. For a deep 
survey on the initial generations of studies in this field, see Gerdtham and Jonsson (2000). 
3 See, for example, Herwartz and Theilen (2003), Herwartz and Theilen (2010), Colombier (2012). Moreover, 
taking into account nonlinearities in the relation between health care and its determinants, Wu et al. (2014) show 
that ignoring technological change and age structure results in an overestimation of income elasticity. 
4 For a survey on the recent literature, see Martin at al. (2011). Another strand of the literature has recently turned 
the attention to the Baumol‟s cost disease (Hartwig, 2008; Colombier, 2012; Bates and Santerre, 2013; Medeiros 
and Schwierz, 2013; and Hartwig and Sturm, 2014), trying to explain health care expenditure as driven by wage 
increases in excess of productivity growth. However, the lack or poor quality of the data, especially for wages, 
makes it impossible to test it for developing countries. Moreover, the Baumol effect is a phenomenon that affects 
mainly developed economies. Thus, that analysis is not under the scope of our study. 
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wide analysis. In this paper, we take a step forward in that direction by considering 156 countries in 
our dataset and separate assessments for OECD and Non-OECD countries as a way of 
distinguishing the effects between developed and developing countries. As far as we are concerned, 
only Xu et al. (2011), using a panel of 143 countries over the period 1995-2008, tries to understand 
the trajectory of health expenditure in developing countries by decomposing the analysis in 
government health expenditure and out-of-pocket payments. In this paper, despite we consider 
more countries and years of observations, we follow a different approach, emphasizing the role of 
sugar intake and comparing the results between developed and developing countries. 
Second, although many recent studies are concerned with stationarity issues, they do not 
take into account the possible dynamics of health care expenditures by controlling for its lag(s).5 
Not controlling for the persistence of the dependent variable, when it is present, generates biased 
estimates (Bond, 2002; Baltagi, 2013). Hence, in this study, we are not only concerned with 
stationarity issues, but also with the persistence in the dependent variable. We employ a dynamic 
panel data analysis where those problems are tackled with a system-GMM estimator. At the same 
time, endogeneity concerns regarding some regressors are taken into account. An additional 
advantage of the dynamic panel models is their ability to identify both short-run impact and long-
run institutional effects (Baltagi, 2013). 
Third, the literature is essentially focused on the total health care expenditure, without 
considering any of its components. Given the aim of this study, we also look at one of its 
components: diabetes expenditures. Besides the importance of income and population aging, Basu 
et al. (2013) emphasize the significant impact that sugar has in increasing the prevalence of 
diabetes. Here, we move a step forward by testing for its impact on diabetes expenditure. This 
analysis is of ultimate relevance as IDF (2015) estimates a significant increase in direct and indirect 
costs related to diabetes. Those costs include an increased use of health services, loss of 
productivity, disabilities and premature mortality. Consequently, this “imposes a large economic 
                                                             
5 Only recently An et al. (2016) provide a dynamic analysis for the impact of public pensions on aggregate health 
spending for a panel of OECD countries. Magazzino and Mele (2012) and Bilgel and Tran (2013) also take into 
account the persistence of the dependent variable in their panel data analysis of the determinants of health care 
expenditures for Italian and Canadian regions, respectively. Despite both use variables in levels, the first does not 
take into account the stationarity issue, which raises doubts on the validity of their estimates. The dynamic panel 
data analysis provided by Xu et al. (2011) suffers from the same problem. 
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burden on individuals and families, national health systems and countries; it therefore represents a 
significant obstacle to sustainable economic development.” (IDF, 2015, p. 58).6 
Finally, despite during recent years studies on the determinants of health care expenditure 
have increased both in methodological complexity and in the identification of causal variables, they 
have given little attention to the role of lifestyle and behaviour. The exceptions are Gerdtham et al. 
(1998), with a particular emphasis on the contractual relations between payers, providers and 
patients, and Hartwig and Sturm (2014).7 However, as far as we are concerned, no study has 
considered the impact of sugar intake on total health care expenditure. 
According to a report issued by the Morgan Stanley in March 2015, sugar consumption per 
capita “has increased almost fivefold over the past century. At the beginning of the 20th century, a 
world population of 1.6 billion people consumed roughly 8 million tonnes of sugar, i.e. 5.1 kg per 
capita. Today, a world population of 7 billion consumes 166 million tonnes of sugar (including 
high-intensity sweeteners), that is 24kg per person, equivalent to around 230 kilocalories per day or 
8% of the total daily energy intake.” (Morgan Stanley, 2015, p. 12). The data provided by Food and 
Agriculture Organization (FAO) on sugar and sweeteners food supply (a proxy for sugar 
consumption) for the period 1961-2011 allow us to conclude that the world food supply of sugar 
and sweeteners has almost tripled over that period (see Figure 1). 
[Insert Figure 1 around here] 
Excessive sugar intake is considered by the medical community to have a direct negative 
impact on health and contributed to the development of several diseases: diabetes, metabolic 
syndrome, obesity, heart and liver diseases, dental caries, and cancers.8 The alarming observation 
                                                             
6 See also Credit Swiss (2013), Kanavos et al. (2012), and Morgan Stanley (2015). 
7 Christiansen et al. (2006) make an attempt to control for tobacco and alcohol consumption using OECD data, but 
their results are not consistent between the samples they use (11 and 15 EU countries). Nevertheless, the aim of 
their study is to analyse the relationship between ageing and the development in the aggregate health care 
expenditure. Panopoulou and Pantelidis (2012) are the first to consider food variables like sugar, fruits and 
vegetables consumption, but their analysis is only focused on finding convergence in per capita health care 
expenditures and in its various potential determinants and not on testing a proper cause-effect relationship 
between health care spending and its determinants. 
8 See, among others, Yudkin (1988), Lustig and Nguyen (2010), Lustig et al. (2012), Basu et al. (2013), Lustig 
(2013), Null (2014), and Jiang et al. (2016). Moreover, Or (2000) shows that sugar consumption is positively 
related to male and female mortality in a sample of 21 OECD countries over the period 1970-1992. 
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that a substantial share of health care expenditure has been devoted to the treatment of those 
diseases in developed economies – considered to be to be related to sugar overconsumption by 
medical experts (Lustig et al, 2012; Lustig, 2013) – brings the issue of health care costs of sugar to 
the agenda. Hence, the study of the impact of sugar on diabetes and health care spending becomes 
of primordial importance for the understanding of their relationship and to provide valuable 
insights on how public authorities might tackle the problems that arise from excessive sugar 
consumption. 
In sum, taking into account, as a starting point, the literature on the determinants of health 
care expenditure and on the health effects of excessive sugar intake, the two main hypotheses that 
we intend to test in this macroeconomic analysis are the following: 
H.1: A rise in sugar intake has a significant positive impact on diabetes expenditures. 
H.2: A rise in sugar intake has a significant positive impact on total health care expenditures. 
 
3. Data and econometric specification 
To explore the impact of sugar on diabetes expenditure and total health care expenditure, 
we use a (panel) database with a cross-sectional component of up to 156 countries and a workable 
temporal component covering the period from 1995 to 2014, for a wide range of variables. 
 
3.1. Data 
The data used in this study comes from several sources. For the dependent variables on the 
diabetes expenditure, the data were collected from various issues of the International Diabetes 
Federation (IDF) Diabetes Atlas for the period 2003-2014. These Atlas provide world countries 
estimates on diabetes prevalence, health expenditure for diabetes and mean diabetes related 
expenditure per person with diabetes (in USD). We use the last two to obtain our diabetes 
expenditure (dependent) variables: the real health expenditure for diabetes per capita 
(rdiab_exp_pc); and the mean diabetes related expenditure per person with diabetes 
(rdiab_exp_ppd). The per capita values in the first variable were computed dividing the health 
expenditure for diabetes by the total population; the consumer price index (base-year, 2010) was 
used to calculate the real values of both variables. The consumer price index and population were 
obtained from the World Development Indicators Database. The data for the dependent variable on 
total health expenditure comes from the World Development Indicators (WDI) Database of the 
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World Bank. The time period is longer than for diabetes expenditures, as the available data ranges 
from 1995 to 2014. The consumer price index (base-year, 2010) was also used to obtain the 
respective real total health care expenditure per capita (rhcepc). From this, we computed the 
respective growth rate (rhcepc_gr). 
To estimate the relation between sugar and health expenditures, we use several measures 
for sugar: sugar and natural sweeteners, in kilocalories per person per day (sugar_swt_kcal); 
refined sugar, in kilocalories per person per day (sugar_ref_kcal); sugar and natural sweeteners, in 
grams per person per day (sugar_swt_gcd); and the percentage of sugar and natural sweeteners 
kilocalories in total kilocalories of food per person per day (sugar_ptot_kcal). These data comes 
from the Food and Agricultural Organization food supply data (FAOSTAT) of the United Nations. 
Our expectation is that higher sugar availability will be associated to increasing health care 
spending with diabetes and in total. 
The control variables are related to the literature on the determinants of health care 
expenditures and consider measures like real GDP per capita (rgdppc) and its growth rate 
(rgdppc_gr), percentage of population under 15 years old (pop014), percentage of population 
above 64 years old (pop65abv), percentage of urban population (urban_pop_ptot), female labor 
force participation rate (lfp_female), public health care expenditure as percentage of total health 
care expenditure (hce_pub_texp), number of hospital beds per 1000 inhabitants (hosp_beds) and its 
growth rate (hosp_beds_gr), and percentage of population exposed to air pollution (pollut_pop). 
The data for these variables were collected from the WDI Database. According to the literature, we 
expect that most of these variables are relevant to explain health care spending. 
Other additional controllers are also considered, like the national diabetes prevalence 
(diab_nprev), percentage of obese adults (obese_prev), market availability of different food items 
(total food, fat, protein, animal products, oils, cereals, fruits, vegetables, meat, fish and alcohol) and 
other proxies for the traditional determinants of health care expenditure. The full list and 
description of variables used in this study, the respective sources and means are reported in Table 
1.9 
[Insert Table 1 around here] 
                                                             
9
 The complete descriptive statistics are provided in Table A1 in Annex. At the bottom of that table is also 
presented the list of countries considered in our sample. 
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With these data we can start to evaluate the validity of the two hypotheses formulated in 
this study (H.1 and H.2). As an initial and simple exercise, we report a set of graphs in Figure 2 
showing the relation between sugar availability and diabetes prevalence, diabetes expenditure and 
total health care expenditure, respectively, for the year of 2010.10 The graphs show a positive 
relationship between sugar and sweeteners food supply/availability (in kilocalories, per person per 
day) and all the other variables. Basu et al. (2013) have already confirmed empirically the positive 
impact of sugar availability on diabetes prevalence, so we will focus on the other three cases. It is 
clear from the picture that countries with higher sugar intake present higher levels of diabetes 
expenditure per capita and per diabetic, and higher total health care expenditure per capita. 
[Insert Figure 2 around here] 
However, this graphical analysis does not take into account the effects of other important 
economic and socio-demographic characteristics on health care expenditures, like the level of 
income per capita and the structure of the population. After controlling for those well-established 
conditionings in the literature (and all time periods available), is sugar intake still playing a role in 
explaining higher diabetes and health care expenditures? The aim of the next section is to provide 
the adequate econometric tools to help us to answer this question. 
 
3.2. Econometric model 
To estimate the impact of sugar on diabetes expenditure and on total health care 
expenditure for all time periods and countries in our dataset, we consider the following two 
dynamic panel data specifications: 
lnrdiab_exp_pcit = α + ρlnrdiab_exp_pcit-1 + βlnsugar_swt_kcalit + γ1rgdppc_grit +  
γ2pop014it + γ3pop65abvit + δtrendt + vi + eit,    (1) 
where i=1,…,156 and t=2003,…,2014; and 
rhcepc_grit = α + ρrhcepc_grit-1 + βsugar_swt_kcalit + γ1rgdppc_grit + γ2pop014it + 
γ3pop65abvit + θXit + δtrendt + vi + eit     (2) 
where i=1,…,156 and t=1995,…,2014. 
                                                             
10
 Similar pictures are obtained for other years, but we choose 2010 because it is the more recent year for which 
we have observations for the higher number of countries in our sample. 
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The coefficient on the lag of the dependent variable (ρ) measures its persistence. The vector 
β captures the impact of sugar availability, while the vectors γj (j=1,2,3) assess the effect of the 
economic conditionings and demographic structure of the population on diabetes and health care 
expenditures. Xit is the vector of the additional control variables (those variables are described in 
Table 1). As in the literature, the time trend is used here as a proxy for medical or technological 
progress. Regarding the last components, νi is the individual effect of each country i, and eit is the 
error term. 
Given the presence of individual effects, νi, the model can be estimated assuming those 
effects as fixed or random. However, the lagged value of the dependent variable would be 
correlated with the error term even if the latter is not serially correlated. This implies that OLS 
estimates (random or fixed effects) will be biased and inconsistent (Baltagi, 2013). The estimators 
that take into account that bias can be grouped into: (i) bias-corrected estimators; and (ii) 
instrumental variables estimators. 
Bias-corrected estimators, like the one proposed by Bruno (2005a, b) – the bias-corrected 
least squares dummy variable estimator (LSDVC) for dynamic panel data models – are suitable 
when the number of individuals (N) is small (and T is not very large). Although T is not large in 
this study, the number of individuals cannot be considered small (N=156). Hence, this estimator is 
not a suitable tool to solve the bias problem caused by the inclusion of the lag of the dependent 
variable in the list of regressors. 
According to the large sample properties of the generalized method of moments (GMM), 
the dynamic estimator proposed by Arellano and Bond (1991) is adequate when there is a clear 
dominance of cross sections (N) over time periods (T) in the sample. This is what happens in our 
panel, which means that this estimator is a more appropriate procedure to solve the bias problem. 
Moreover, it allows estimating the dynamic model in a more consistent and efficient way. 
Taking first differences of equations (1) and (2), levels of the explanatory variables can be 
used as instruments to avoid correlation between the respective lagged dependent variable and the 
country-specific effects. Arellano and Bond (1991) also proposed a variant of the GMM estimator, 
namely the two-step estimator, which utilizes the estimated residuals in order to construct a 
consistent variance-covariance matrix of the moment conditions. The two-step estimator is 
asymptotically more efficient than the one-step estimator and relaxes the assumption of 
homoscedasticity, which generates efficiency gains. 
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Arellano and Bover (1995) and Blundel and Bond (1998) suggested additional moment 
conditions, since, as long as valid, they increase the efficiency of the estimators. This GMM 
estimator that combines the moment conditions of the model in first differences and those of the 
model in levels (differences are used as instruments for the level equations) is known as the 
system-GMM estimator. This allows estimating the model with higher accuracy, reducing the finite 
sample bias (Bond, 2002; Baltagi, 2013).11 
An additional problem that we have to deal with is the “too many instruments problem”. 
Too many instruments may result in over-fitting biases. When the number of time periods is 
relatively large, this over-fitting becomes serious. The consequent large collection of instruments, 
even if individually valid, can be collectively invalid because they over-fit endogenous variables 
(Doornik et al., 2002; Roodman, 2009a, b). They also weaken the Hansen test of overidentifying 
restrictions used to check instrument validity. To minimize the over-fitting problem we use the 
collapse alternative suggested by Roodman (2009b). This procedure allow us to create one 
instrument for each variable and lag distance, rather than one instrument for each time period, 
variable and lag distance as it divides the moment conditions in the GMM equations into groups. 
Then, the conditions in each group are added to form a smaller set of conditions. 
 
4. Empirical results 
In this section are presented and discussed the empirical results. First, we analyse the 
evidence from the diabetes expenditure. Then, we proceed with a more extensive, deeper and 
enlightening analysis of the impact of sugar intake on total health care expenditure. 
 
4.1. Diabetes expenditure 
The results of system-GMM estimations for the diabetes specifications are reported in 
Table 2. We start by showing the results for the case in which the log of real health expenditure for 
diabetes per capita (lnrdiab_exp_pc) is the dependent variable; in a second set of results the 
                                                             
11 For this to be valid, the system-GMM requires the stationarity of the variables and the lack of correlation 
between the first-differences of the instruments and the specific effects (Baltagi, 2013). Im-Pesaran-Shin and ADF 
Fisher-type panel unit root tests were performed for the dependent and independent variables used in this study. 
The results are presented in Annex (see Table A.2) and show that the null hypothesis that all panels contain unit 
roots is rejected for all the variables that we use in our regressions. This also justifies why the dependent variable 
is in levels in the diabetes specification and in growth rates in the case of total health care. 
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dependent variable is replaced by the log of mean diabetes related expenditure per person with 
diabetes (lnrdiab_exp_ppd).12 The use of these two measures allows us to account for the relative 
importance of spending on diabetes in the total population and in the population affected by the 
disease. The first measure makes also the results more comparable with the ones for total health 
care expenditure per capita. 
A concern in this kind of empirical analysis is the possibility that the explanatory variables 
are endogenous. The system-GMM estimator employed here controls for the potential endogeneity 
of some covariates (lag of the dependent variable, growth of real GDP per capita and sugar and 
sweeteners availability) by using their lagged instruments in the first-difference and level 
equations. The other variables are considered exogenous (pop014, pop65abv, and trend) and 
instrumented with their contemporaneous values.13 
Two-step results using robust standard errors corrected for finite samples are reported in 
parenthesis and the respective significance level is indicated with stars. The number of 
observations, countries, and instruments, as well as the p-values for the Hansen, Difference-in-
Hansen, and autocorrelation tests are reported at the bottom of the Table 2. 
[Insert Table 2 around here] 
The system-GMM estimator accounts for the dynamic bias that results from the inclusion 
of the lagged dependent variable in the specifications. However, the problem may not completely 
disappear, as this estimation method assumes weak exogeneity of the explanatory variables. This 
means that they can be affected by the past and current values of diabetes expenditure but must be 
uncorrelated with future realizations of the error term, i.e. future unanticipated shocks to diabetes 
expenditure should not affect the current value of the explanatory variables. The statistical validity 
of this assumption is supported by the results of the Hansen-test, which, in general, does not reject 
the validity of the overidentifying restrictions (except in regression 6). The results for the 
difference-in-Hansen test are also considered to assess the validity of the GMM instruments of the 
                                                             
12 Both variables are stationary as required. See panel unit root tests in Table A.2 in Annex. In some experiments – 
not reported here but available upon request – suggested by one of the referees, we also considered these variables 
and sugar intake in growth rates, but the conclusions did not change. 
13 More specifically, the respective lagged values and the other explanatory variables are used as instruments in 
the first-differences equation and their first-differences are used in the levels equation. They are collapsed to avoid 
the problem of having too many instruments. 
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levels equation: their validity is not rejected either (with the exception of regression 6). Finally, the 
tests for autocorrelation of the differenced residuals – AR(1) and AR(2) – reject second-order 
autocorrelation, further supporting the validity of the instruments used. Hence, one lag of the 
dependent variable has proved to be sufficient to account for its persistence. 
The empirical results reported in Table 2 are very robust in showing that sugar and natural 
sweeteners availability has a significant positive impact on diabetes expenditure per capita and per 
diabetic. In particular, and since we have a log-log specification, a 1% increase in sugar availability 
is estimated to generate an immediate increase in real diabetes expenditure per capita of around 
2.5%. In the long-run the impact will be even higher: 4.70% (=2.5/(1-0.47)). This means that for 
each additional teaspoon of added sugar, diabetes expenditure will rise, on average, by roughly 
26.8% in the long-run.14 When we look only at the population of diabetics, the estimated magnitude 
of the impact is lower (0.8%-0.9%) in the short-run, but in the long-run it is closer: 4.06% (=0.8/1-
0.79). Nevertheless, what does this mean in terms of the actual value of this impact in dollars? The 
mathematical correspondence between the two coefficients can be better understood if we look at 
the impact in terms of the original unit of measure (dollars) than in terms of percentages. 
As we have a log-log relation between the dependent (diabetes) variables and sugar intake, 
the analysis is made in terms of percentages. The fact of the magnitude of the impact in percentage 
is higher in per capita than in per diabetic terms does not mean that the impact in dollars is higher 
in the first than in the second case. In the first analysis, as we are dividing diabetes spending by 
more people (population), the values in dollars will be lower than when we divide it by only the 
diabetic people. Hence, the magnitudes of diabetes spending per capita and per diabetic in dollars 
will be different and may lead to opposite results when we analyse the results on that basis. For 
                                                             
14 Considering that a teaspoon corresponds to 4 grams or 16 kilocalories of sugar and that this amount represents 
5.7% of the mean of sugar_swt_kcal (i.e. 100*16/279.2; see Table A.1 in Annex), we just need to multiply 5.7 by 
4.7 to reach the value of 26.8%. This is a large effect. However, the level of sugar availability/intake also reached 
a huge level in the time period considered in this analysis (2003-2014; see, for example, Figure 1). Hence, a small 
increase in sugar intake during this period can have a large effect on people‟s health conditions, promoting the 
development of diabetes in more and more people and, consequently, increasing quite rapidly the level of 
spending with diabetes. Considering the high levels of sugar consumption observed over that period (see also: 
Credit Suisse, 2013; IDF, 2015; and Morgan Stanley, 2015) it is not unlikely that one more teaspoon of sugar 
intake, on the top of an already high level of consumption, might have a huge and higher effect on diabetes 
spending than it might have had in the past, when the average consumption was lower and, for that reason, one 
additional teaspoon of sugar would not increase so much the costs to treat a few more diabetics. 
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example, considering the means of diabetes expenditure per capita (85.05) and per diabetic 
(909.00) – see Table A.1 in Annex – if we multiply them by the respective estimated long-run 
coefficients (4.70% and 4.06%, respectively), we get the following marginal effects on the average, 
respectively: 4.0 dollars (=4.70%*85.05) and 36.9 dollars (=4.06%*909.00). Thus, when sugar 
intake increases by 1%, we estimate that diabetes expenditure per capita will increase, in the long-
run, approximately 4.0 dollars, while in per diabetic terms the increase will be approximately 36.9 
dollars. A similar pattern in the magnitudes can be found if we look, instead, at the short-term 
impact in dollars on the average. 
Similar findings are obtained when we split the sample in OECD and Non-OECD 
countries. One important result that stands from that analysis is the fact that the impact of sugar on 
diabetes expenditure is higher (in magnitude) in the first group. Developed countries might have 
more resources to deal with the „problem‟, but probably the „problem‟ has already reached higher 
proportions there (Lustig et al, 2012; Lustig, 2013; Credit Suisse, 2013; Morgan Stanley, 2015). 
In sum, these results are in line with our expectation, confirming our first hypothesis that a 
higher sugar intake increases diabetes expenditure. This is the case after controlling for income per 
capita, population, trend for medical/technological progress and even for diabetes prevalence. Real 
GDP per capita has a significant (positive) coefficient only in the specifications where 
lnrdiab_exp_pc is the dependent variable and when its stationary growth rate is used (see columns 
2 and 3 in Table 2). Regarding the effects of the structure of population, population aging, in 
particular, presents a significant impact on diabetes expenditure: it increases when the share of 
elderly people is higher. Nevertheless, the effect is not very relevant in Non-OECD countries. As 
expected, technological changes are positively associated with diabetes expenditure. Finally, 
diabetes prevalence boosts diabetes expenditure per capita, especially in Non-OECD countries, but 
not the average spending per diabetic. As more diabetics will require more resources, in per capita 
terms we observe an increase in spending, but in per diabetic terms the expenditure will not change 
much (as more resources are divided by more patients). 
The prevalence of obesity was also considered in some additional experiments reported in 
Table A.3 in Annex, but no significant effects were found for the coefficient on that variable 
(obese_prev). One reason for that lack of significance might be the fact that a person does not need 
to be obese to be diabetic. There are many people not suffering from obesity but that are diabetic 
and obese people that are not diabetic. The issue that obesity causes diabetes is not clearly 
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established in the literature. For example, Lustig (2013, Ch.8), says that in the US “Twenty percent 
of morbidly obese adults have completely normal metabolic status, no evidence of disease, and 
normal longevity. [Moreover] …50 percent of women and 20 percent of men who are categorized 
as normal on the basis of their BMI are actually obese based on their carriage of visceral (bad) fat. 
[…] Bottom line, it‟s your visceral fat, in particular your liver fat, that counts.” 
Thus, the “BMI obesity” might not be the best way to test whether obesity is increasing 
diabetes spending; we should look instead at the “visceral obesity”, because that can cause more 
damage. However, those data are not available for a macro-analysis like this. Nevertheless, we 
decided to explore this issue in greater detail and considered instead a variable for obesity that 
corresponds to the residuals of the regression of obesity prevalence on sugar intake (resid_obese). 
That new variable represents the part of obesity prevalence that is not explained by sugar intake. 
We did the same for diabetes prevalence and created the variable resid_diab (See Table A.3 in 
Annex).15 The results confirm the relevance of diabetes prevalence (the part not explained by sugar 
intake) on diabetes expenditure per capita but not on per diabetic. The part of obesity prevalence 
not explained by sugar intake remains insignificant. Thus, by the reasons indicated above, obesity 
prevalence by itself might not indeed be driving diabetes spending. Sugar intake is playing a more 
important role on that matter, either for thin or fat people. 
 
4.2. Total health care expenditure 
The practical limitations inherent to the diabetes expenditure variables – like the short time 
period of data available, the method used by the IDF to obtain the respective estimates (see IDF 
Diabetes Atlas for further details), and the fact of some missing observations had to be generated 
by linear interpolation – are detrimental to proceed with the analysis of the impact of sugar intake 
on total health care expenditure. In this case, the time period is longer and the quality of the data is 
much less questionable. Furthermore, another of the aims of this study is precisely to check the 
hypothesis of whether sugar and natural sweeteners availability is driving an increase in total health 
care spending (hypothesis H.2). 
The first set of results of the system-GMM estimations for the total health care 
specifications is reported in Table 3. In this initial analysis, we consider several measures for sugar 
and (only) the basic controllers referenced in the literature (and used in the diabetes regressions 
                                                             
15 We are grateful to one anonymous referee for bringing this issue to our attention. 
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above); income, population and „technological‟ trend. Due to the required stationarity properties, 
the dependent variable is not in levels but in growth rates: the growth rate of real health care 
expenditure per capita (rhcepc_gr) – see Table A.2 in Annex. 
The two-step system-GMM estimator controls for the potential endogeneity of the lag of 
the dependent variable, growth of real GDP per capita and sugar and sweeteners availability by 
using their lagged instruments in the first-difference and level equations. All the other variables are 
considered exogenous and instrumented with their contemporaneous values.16 In this case, the 
Hansen-test never rejects the validity of the overidentifying restrictions, and the results for the 
difference-in-Hansen test also support the validity of the GMM instruments of the levels equation. 
Moreover, the autocorrelation tests reject second-order autocorrelation, as required, further 
supporting the validity of the instruments used. 
[Insert Table 3 around here] 
We start by ignoring the stationarity issues and estimate a model in logs (see column 1 in 
Table 3) to compare the results with the literature that looks at the elasticity of income. In this case 
two lags of the dependent variable are needed to eliminate the second-order autocorrelation. The 
results show that an increase of 1% in the kilocalories of sugar and natural sweeteners lead to an 
immediate rise of 0.26% in real total health care expenditure per capita; in the long run it will 
represent an increase of 0.93%.17 Thus, we have here clear evidence of a significant effect of sugar 
intake on health care expenditure. 
The results for the controllers are in line with the literature, showing that real health care 
expenditure per capita increases with real GDP per capita, population aging and medical or 
technological progress. In particular, they show that the (long-run) income elasticity is well below 
one (0.46%), confirming that health care is a necessity (rather than a luxury) for this sample of 
more than 150 countries. 
Stationarity is a concern in these models, so we proceed by only considering stationary 
series. Columns (2)-(7) in Table 4 report results for several measures of sugar: logarithm of sugar 
                                                             
16 Similarly to what we have done in the diabetes estimations, lagged values of the endogenous variables and the 
other explanatory variables are used as instruments in the first-difference equation and their first-differences are 
used in the levels equation. They are collapsed to avoid the problem of having too many instruments. 
17 Taking into account the dynamics of the adjustment in the model: 0.93=0.26/[1-(0.94-0.22)]. 
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and sweeteners in kilocalories (per person, per day), growth rate,18 sugar and sweeteners in 
kilocalories (per person, per day), percentage of total food, refined sugar (per person, per day), and 
sugar and sweeteners in grams (per person, per day). The results are very robust in showing a 
significant positive impact of sugar on the growth rate of total real health care expenditure per 
capita, corroborating our hypothesis H.2 that a higher sugar intake increases total health care 
expenditure. Moreover, they support the observed growth in health expenditure devoted to diseases 
or health conditions related to sugar overconsumption (Lustig et al, 2012; Lustig, 2013; Credit 
Suisse, 2013; Morgan Stanley, 2015). 
The growth rate of real GDP per capita and the „technological‟ trend also present the 
expected positive and significant impact. The results for the structure of the population are not very 
robust but they support the idea that health care expenditure tend to be higher when the percentage 
of young (and, in some cases, elderly) people in the population is higher. 
Besides income, population structure and medical/technological progress, other factors are 
considered in the literature to explain health care expenditure: percentage of urban population (Leu, 
1986; Gerdtham et al., 1992; Wang, 2009, Hosoya, 2014), female labor force participation 
(Gerdtham et al., 1992; Christiansen et al., 2006; Hosoya, 2014), health care systems characteristics 
(Gerdtham et al., 1992; Hitiris and Posnett, 1992; Barros, 1998; Christiansen et al., 2006; Mosca, 
2007, Wang, 2009; Baltagi and Moscone, 2010; Hosoya, 2014), and health care supply (Gerdtham 
et al., 1992; Christiansen et al., 2006; Mosca, 2007; Wang, 2009; Magazzino and Mele, 2012; 
Hosoya, 2014). 
To control for the effect of urbanization on the growth rate of real per capita health care 
expenditure, we use the percentage of urban population (urban_pop_ptot). As urban areas can 
benefit from economies of scale in terms of the availability of health care resources and lower 
travel costs, we expect a negative impact on health expenditure. 
The percentage of female labor force participation rate (lfp_female), ages 15-64, is used 
here as a proxy for the substitution of formal care by informal care, leading to a transition of health 
care from the family to institutions, and therefore, to higher health care expenditure (Gerdtham et 
al., 1992; Christiansen et al., 2006). When women participate in the labor force, they have less time 
to take care of their families (especially children and elderly) when someone is sick or health 
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 Note that all sugar variables are stationary in levels (see Table A.2 in Annex), so we will proceed the analysis 
using levels instead of growth rates. Nonetheless, the robustness of our findings is not affected. 
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conditions deteriorate. Hence, the family has to spend more in formal/external health care 
assistance. For example, taking care of elderly was a responsibility of the family, while today this 
is a role played by various health institutions. Working women also have less time and availability 
to prepare healthy meals daily, tending to rely on processed fast-food and ready meals, which 
contribute to the deterioration of the family health, diseases and, consequently, more spending with 
health care. 
The health system characteristics are usually defined by health financing parameters, the 
kind of provider payment mechanisms and service provision, but the ability to test these variables 
is limited due to data availability. The better proxy we can use to „accommodate‟ those effects is 
the share of public health care expenditure (hce_pub_texp). It is not clear whether a higher 
participation of the government in health care expenditure might increase or decrease it, so we 
abstain from hypothesize a sign for its coefficient.19 
Regarding health care supply, studies with OECD countries rely on the number of hospital 
beds or physicians. We control for this effect using the growth rate of the number of hospital beds 
(hosp_beds_gr), but later – in a sensitivity analysis – we will replace it by the second. We 
conjecture that the higher is the supply, the more the health care expenditure will grow. 
Additionally, we also consider one environmental conditioning: air pollution. Magazzino 
and Mele (2012) are the first to raise this issue by using the percentage of households who 
complains about air pollution. We use the percentage of population exposed to levels exceeding 
WHO guidelines (pollut_pop) and expect that pollution can contribute to an increase in general 
health problems and increase health care spending. 
The results with these new controllers are presented in Table 4 for sugar and natural 
sweeteners in kilocalories per capita per day (see columns 1-3) and for the respective percentage in 
total food supply (see columns 4-6). We also report the results for separate samples of OECD and 
Non-OECD countries. 
[Insert Table 4 around here] 
                                                             
19 See Leu (1986), Culyer(1990) and Gerdtham et al. (1992) for a discussion on the issue. Several other studies 
have considered this proxy; see, for example, Hitiris and Posnett (1992), Christiansen et al. (2006), Baltagi and 
Moscone (2010) and Hosoya (2014). 
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Despite controlling for all those new factors, sugar intake remains an important determinant 
of health care expenditure, not only for the whole sample but also for the sub-samples of OECD 
and Non-OECD countries. In particular, when sugar and natural sweeteners availability increases 
by 10 kilocalories (or one percentage point relatively to total food supply – see column 4 instead), 
the growth rate of real health care expenditure per capita rises, on average, by around 0.9 (or 2.3) 
percentage points (p.p.), ceteris paribus.20 As the speed of the adjustment is very quick (0.83=1-
0.17), the respective long-run impact is only slightly higher (1.1 p.p. or 2.8 p.p., for each case, 
respectively). Thus, we estimate that, on average, for each additional teaspoon (4 grams or 16 kcal) 
of added sugar intake, health care expenditure per capita will grow an additional 1.8 p.p. 
(=0.11*16) in the long-run. 
This is a very striking finding as it shows that a small increase in sugar intake (on average) 
will have a huge impact on health care spending. Like we emphasized in the analysis for diabetes 
expenditure, this means that the sugar problem is there and that it has reached such a level that 
additional sugar intake has had severe health consequences, being then reflected in a significant 
increase in health care expenditure. The level of sugar availability reached such a high level in the 
time period considered in our sample (1995-2014 – see, for example: Figure 1; Credit Suisse, 2013; 
IDF, 2015; Morgan Stanley, 2015) that a small increase in sugar availability/intake, during that 
period, has a large effect on people‟s health conditions and consequently on health care spending.  
Therefore, it is quite likely that one more teaspoon of sugar intake, on the top of an already high 
level of sugar consumption, might have a huge and higher effect on health care spending than it 
might have had in the past, when the average consumption was lower and when, for that reason, 
one additional teaspoon of this “poison” would not harm people‟s health so much… “sola dosis 
facit venenum”, i.e. the dose makes the poison. 
This is a problem to which public authorities and governments have to give a closer 
attention in order to avoid the deterioration of public health, with severe social and economic costs 
for the society, in general, and constraints concerning the financial resources devoted to health care 
by the governments, in particular. 
                                                             
20 An increase of 10 kilocalories represents approximately an increase of 3.6% relatively to the mean of 
kilocalories of sugar and natural sweeteners in the sample (see Table A.1 in Annex). Hence, an increase of 10% in 
sugar availability relative to its mean (around 28 kilocalories) will correspond to an immediate rise of about 2.5 
p.p. in the growth rate of real total health care expenditure per capita (roughly the same we get when we consider 
a 1 p.p. increase in the percentage of sugar relatively to total food). 
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When we look at the groups of OECD and Non-OECD countries separately, we also 
observe the important role of sugar, but surprisingly the effect is more intense in the group of Non-
OECD countries.21 One possible explanation for this might be the fact of their initial spending on 
health being very low, but the pressure exerted by a rise in people with health problems have 
forced them to spend more on health. Thus, like in the convergence models, where poor or 
developing countries tend to grow faster given their lower initial conditions, these countries will 
also tend to present a higher growth in health care spending to a (similar) deterioration in health 
conditions caused by more added sugar in the diet. At the same time, some developing countries 
have improved their economic conditions allowing them to increase spending more generously in 
social areas like education, health and culture. 
Regarding the control variables, the growth rate of real GDP per capita remains as the main 
robust determinant: for each 1 p.p. increase in real GDP growth rate, real health care expenditure 
per capita grows an additional 1.1 p.p., on average. The results for the structure of population are 
mixed: while the share of young people in the population seems to matter, the percentage of elderly 
people has not proved to be relevant. Zweifel et al. (1999) and Christiansen et al. (2006) argue that 
proximity to death can be a better proxy for population aging than pop65abv, but due to lack of 
data for most of the countries in the sample we cannot consider that variable.22 
The estimated effect of urbanization for the whole sample is negative, as expected, but not 
statistically significant. Surprisingly (or not), health care expenditures grow faster in urban areas in 
OECD countries. This might be an indirect consequence of the deterioration of the quality of life in 
urban areas in developed countries, not overcome by the expected economies of scale from the 
availability of health care resources and lower travel costs. 
The results for the percentage of female labor force participation are, in general, in line with 
the literature (Gerdtham et al., 1992; Christiansen et al., 2006): the substitution of formal care by 
informal care leads to higher health care spending. This effect is particularly intense in the group of 
less developed countries. The costs involved in that substitution might be higher due to the lack of 
a proper public health care structure. 
                                                             
21 Note that for the group of OECD countries two lags of the dependent variable are needed to eliminate the 
second-order autocorrelation. 
22 In the sensitivity analysis presented in Annex (see Table A.4), we consider other proxies for population aging. 
In particular for males, we find that aging (% surviving until 65 and life expectancy) has indeed the expected 
increase in health care spending. 
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The growth rate of health care spending per capita is not affected by the percentage of 
public health care expenditure, when we consider the overall sample and Non-OECD countries 
only. However, a significant negative effect is observed for the group of OECD countries. Culyer 
(1990) argues that open-financing systems, usually characterized by multiple finance sources 
(insurance companies) and by fee-for-service remuneration, offer little incentive for providers and 
little opportunity for financiers to restrain spending. Conversely, closed systems – those 
characterized by one or few finance agents, public health care services and global budgets for 
hospitals – can be more efficient in controlling spending. Hence, a higher participation of the 
government in health care expenditure seems to contribute to a more rational allocation of the 
resources in the OECD countries. This efficiency in managing health care services can also be 
considered to explain why no significant effects are found regarding the supply-side 
(hosp_beds_gr) for this group. Nevertheless, the growth rate of the number of hospital beds has the 
expected significant positive impact in the whole sample and for Non-OECD countries. 
Finally, we confirm that the higher the percentage of population exposed to pollution, the 
more health care expenditure will grow (for the whole sample and Non-OECD countries). In fact, 
more pollution will deteriorate general health conditions, putting pressure on health care spending. 
In the next set of regressions, we consider some additional variables that are not usually 
considered in this literature, but – given the aim of this study – may impact on health care 
expenditure. The results are reported in Table 5, where, once again, only stationary variables are 
used in the estimations. In the first two regressions we control for (the change in) diabetes and 
obesity prevalence (diab_nprev and obese_prev). These are two health conditions commonly 
linked to excessive sugar consumption (Yudkin, 1988; Basu et al., 2013; Lustig et al, 2012; Lustig, 
2013). Hence, we test whether, after controlling for these conditions, sugar is still exerting its 
significant and positive effect on health care spending. The results are clear in confirming it and in 
showing that those two variables per se have no relevant impact. In fact, similarly to Basu et al. 
(2013), we can say that when obesity and diabetes prevalence are not included (see column 1 in 
Table 4) the magnitude of the sugar effect is not substantially amplified, which might suggest that 
obesity and diabetes do not account for the major part of the important impact that sugar 
availability/intake has on the growth rate of health care expenditure per capita.23 
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 These results must be analysed with some care due to some data limitations related to diabetes and obesity 
prevalence: the number of time periods available for both variables is reduced (especially for diabetes prevalence: 
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[Insert Table 5 around here] 
To explore this issue in greater detail we also consider here the “net” diabetes and obesity 
prevalence variables used in the analysis for diabetes expenditure: resid_obese and resid_diab. 
They represent the part of diabetes and obesity prevalence that is not explained by sugar intake. 
The results are reported in columns 3 and 4 in Table 5 and they show that “net” obesity prevalence 
remains insignificant. The way obesity is measured (using the BMI, which is not a consensual 
measure for obesity), the fact that some obese people might not be unhealthy and some thin people 
might be (by the reasons pointed by Lustig, 2013, Ch.8) and the lower number of observations may 
justify this result. 
On the contrary, the part of diabetes prevalence not explained by sugar intake is now 
presenting a significant coefficient. This means that we need to remove the effect of sugar intake 
on diabetes prevalence – highlighted by Basu et al. (2013) – to uncover the “net” impact of 
diabetes prevalence on the growth rate of total health care expenditure. Otherwise, the correlation 
between both regressors is hiding the relevance of diabetes prevalence on health care spending. 
Thus, we can conclude that “net” diabetes prevalence is not only consistently affecting diabetes 
expenditure, but also total health care spending. Nevertheless, sugar intake is still playing an 
important role in both cases. 
In the following set of regressions (columns 5-7), we control for total food supply, nutrients 
(fat, protein, oils), other types of food (cereals, fruits, vegetables, oils, meat, fish) and alcohol. The 
inclusion of these variables did not affect the results and sugar availability remains with a 
significant positive coefficient. Only the quantity of fat has proved to have a similar significant 
impact on health care expenditure. When we disaggregate it in animal fat and oils (and types of 
foods), we conclude that the effect comes essentially from the consumption of vegetable oils (see 
columns 7 and 8).24 This result may sound controversial, however it is backed up by some recent 
                                                                                                                                                                                                
2003-2014); they represent estimated values obtained by the IDF (for diabetes prevalence) and WHO (for obesity 
prevalence); and some missing data had to be generated by linear interpolation. 
24 We also considered the fraction of each food in total, but results remained unchanged. They are not reported 
here, but there are available upon request. In Table A.4 in Annex, we provide a sensitivity analysis where the 
controllers are replaced by other related proxies. Some robustness checks are also reported in Tables A.4 and A.5 
in Annex. Table A.5 reports results with different lags for the sugar variable and with two different estimators: a 
differences-GMM estimator and a fixed-effects estimator. Table A.6 presents some results by regional areas using 
a fixed effects estimator. In general, the main results and conclusions did not change. 
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medical research that shows that vegetable oils may not be as healthy as we think (see: Credit 
Suisse, 2015; National Obesity Forum, 2016; and the references therein). For example, the National 
Obesity Forum Report (2016, p. 9) states that “Omega-6 rich vegetable oil (such as sunflower and 
corn oil), linked to the increased risk of death, coronary heart disease, and cancer in humans cannot 
be considered safe.” Hence, it is quite likely that a rise in the consumption (in some) vegetable oils 
is linked to an increase in health care expenditure. Nevertheless, as the recommendations on fat 
consumption and its impact on health are currently subject to a huge debate, more research needs to 
be done to establish a clear link between fat consumption, health and health care expenditure. 
 
5. Conclusions 
This study provides evidence to support the thesis that the rise in sugar availability/intake is 
leading to an increase in health care expenditure. We start by looking at the impact of sugar intake 
on diabetes expenditure and then on total health care expenditure. We build this macroeconomic 
analysis upon the standard literature on the determinants of health care expenditure and we estimate 
a dynamic panel data model over a sample of 156 countries for the period 1995-2014. 
The results reported in this paper show that an increase in sugar availability/intake leads to 
a significant rise in diabetes expenditure (per capita and per diabetic) and in the growth rate of total 
health care expenditure per capita. We estimate that, on average, in the long-run, for each 
additional teaspoon of added sugar per person, spending on diabetes per capita will rise 26.8% and 
the growth rate of total health care expenditure per capita will augment 1.8 percentage points. This 
is also observed, with slightly different magnitudes, in a separate analysis for OECD and Non-
OECD countries. The results are consistent after controlling for income per capita, population, 
medical/technological progress, urbanization, female participation in the labor force, share of 
public health expenditure, hospital beds, air pollution, among others. 
John Yudkin (Yudkin, 1988), first, and Robert Lusting (Lustig, 2012), later, have very 
eloquently called the attention to the huge negative impact of sugar consumption on health 
(incidence of coronary thrombosis, dental caries, obesity, diabetes and liver disease, gout, 
dyspepsia and some cancers). This study embraces that knowledge and moves a step forward, 
putting the emphasis on the economic costs of excessive sugar intake. Our findings are striking, as 
they show that a small increase in sugar intake has a huge impact on diabetes expenditure and total 
health care spending. Sugar is not only causing the health problems highlighted by Yudkin (1988) 
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and Lustig (2012) but also boosting health care expenditures. Public authorities must give a closer 
attention to this issue in order to avoid the deterioration of public health, severe social and 
economic costs, and pressure on financial resources devoted to health care. Some countries have 
already introduced the so called “sugar tax”: Denmark, France, Norway, Mexico, and South Africa. 
More recently, Portugal and the UK announced to do the same in 2017 and 2018, respectively. 
Although these measures can raise people‟s awareness to the problem, a more profound work has 
to be done in terms of information and education. 
We must stress that our analysis only takes into account the direct costs of excessive sugar 
and natural sweeteners intake over diabetes and health care expenditures. We believe that the 
scenario can be even darker if indirect costs like increased use of health services, loss of 
productivity, absenteeism, disabilities, and premature mortality are considered. Several studies 
refer that the indirect costs are a significant part of the problem, maybe even more significant than 
the direct costs (Credit Swiss, 2013; Kanavos et al., 2012; Morgan Stanley, 2015). However, due to 
the specific aim of this study and data limitations for most of the countries in our sample, we do not 
consider indirect costs in this analysis. In future works it would be interesting to conduct a study 
where those costs are taken into account. 
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Table 1 – Description of the variables and sources 
Variable Description Source Mean 
rdiab_exp_pc Real health expenditure for diabetes per capita (constant 2010 USD). IDF 85.05 
rdiab_exp_ppd Mean diabetes related expenditure per person with diabetes (constant 2010 USD). IDF 909.00 
rhcepc Real total health care expenditure per capita (constant 2010 USD). WDI 894.82 
rhcepc_gr Annual growth rate of real health care expenditure per capita (in %). Own calculation 0.40 
sugar_swt_kcal Sugar and natural sweeteners food supply, in kilocalories per person per day. FAOSTAT 279.21 
sugar_ref_kcal Sugar refined food supply, in kilocalories per person per day. FAOSTAT 255.14 
sugar_swt_gcd Sugar and natural sweeteners food supply/quantity, in grams per person per day. FAOSTAT 81.11 
sugar_ptot_kcal % of sugar and natural sweeteners kilocalories in total food per person per day. FAOSTAT 9.98 
sugar_swt_kcal_gr Annual growth rate of sugar and sweeteners food supply (in %). Own calculation 0.86 
rgdppc Real GDP per capita (constant 2010 USD). WDI 11093.1 
rgdppc_gr Annual growth rate of real GDP per capita (in %). WDI 2.54 
pop014 % of population aged 0-14 years. WDI 30.91 
pop65abv % population aged 65 and above. WDI 7.28 
urban_pop_ptot % of urban population. WDI 56.09 
lfp_female Labor force participation rate, female (% of female population ages 15-64). WDI 56.25 
hce_pub_texp Public health care expenditure (% of total health care expenditure). WDI 57.26 
hosp_beds Number of hospital beds per 1000 inhabitants. WDI 3.43 
hosp_beds_gr Annual growth rate of hospital beds (in %). WDI -1.54 
pollut_pop Air pollution: % population exposed to levels exceeding WHO guidelines. WDI 73.11 
diab_nprev Diabetes national prevalence (% adult population, 20-79 years). IDF 7.29 
obese_prev Percentage of obese adults (18 years and above), i.e. with BMI>=30 Kg/m2. WHO 16.13 
total_kcal Total food supply, in kilocalories per person per day. FAOSTAT 2713.96 
total_fat_gcd Total fat supply/quantity, in grams per person per day. FAOSTAT 80.09 
total_prot_gcd Total protein supply/quantity, in grams per person per day. FAOSTAT 76.26 
anim_prod_fat_gcd Animal products fat supply/quantity, in grams per person per day. FAOSTAT 36.42 
oils_gcd Vegetable oils and oil crops supply/quantity, in grams per person per day. FAOSTAT 57.62 
anim_prod_prot_gcd Animal products protein supply/quantity, in grams per person per day. FAOSTAT 34.13 
cereal_kcal Cereals food supply, in kilocalories per person per day. FAOSTAT 1097.82 
fruit_kcal Fruits food supply, in kilocalories per person per day. FAOSTAT 102.86 
vegs_kcal Vegetables food supply, in kilocalories per person per day. FAOSTAT 55.65 
oils_kcal Vegetable oils and oil crops food supply, in kilocalories per person per day. FAOSTAT 317.99 
meat_kcal Meat food supply, in kilocalories per person per day. FAOSTAT 217.32 
fish_kcal Fish and seafood food supply, in kilocalories per person per day. FAOSTAT 35.91 
alcohol_kcal Alcoholic beverages food supply, in kilocalories per person per day. FAOSTAT 76.88 
unemp_rate Unemployment rate (% of total labor force) WDI 8.86 
surv65_fem Survival to age 65, female (% of cohort). WDI 74.32 
surv65_male Survival to age 65, male (% of cohort). WDI 65.16 
life_exp_fem Life expectancy at birth, female (in years). WDI 70.80 
life_exp_male Life expectancy at birth, male (in years). WDI 66.00 
pop_dens Population density (people per square km of land area). WDI 376.70 
lfp_ratio_fm Ratio of female to male labor force participation rate (in %). WDI 68.43 
hce_pub_gdp Public health care expenditure (% of GDP). WDI 3.67 
physicians Number of physicians per 1000 inhabitants. WDI 1.57 
pollut_expos Air pollution: mean annual exposure (micrograms per cubic meter). WDI 17.85 
Sources: International Diabetes Federation (IDF), Diabetes Atlas, several issues (www.diabetesatlas.org). Food and Agriculture 
Organization of the United Nations (FAOSTAT), Food Supply Database (http://faostat.fao.org/site/345/default.aspx). World Bank, 
World Development Indicators (WDI) Database (http://data.worldbank.org/data-catalog/world-development-indicators). World 
Health Organization (WHO) Global Infobase (https://apps.who.int/infobase/). 
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Table 2. Diabetes expenditure 
Dep.Variable: lnrdiab_exp_pc lnrdiab_exp_ppd 
 All All All OECD Non-OECD All All OECD Non-OECD 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
          
L.lnrdiab_exp_pc 0.4648** 0.4727*** 0.4729*** 0.1821* 0.6686***     
 (0.1883) (0.1575) (0.1606) (0.1075) (0.1331)     
L.lnrdiab_exp_ppd      0.7998*** 0.7948*** 0.4781** 0.9291*** 
      (0.1126) (0.1106) (0.1891) (0.0361) 
lnsugar_swt_kcal 2.9522** 2.3674** 2.5071** 1.8206*** 1.2941** 0.8839** 0.8327** 0.5596* 0.4310* 
 (1.1480) (0.9415) (1.0525) (0.6833) (0.6321) (0.3753) (0.3685) (0.3029) (0.2601) 
lnrgdppc -0.2107         
 (0.4814)         
rgdppc_gr  0.0142** 0.0140** 0.0064 0.0066 0.0009 0.0009 0.0049 -0.0044 
  (0.0068) (0.0069) (0.0080) (0.0054) (0.0045) (0.0044) (0.0076) (0.0032) 
pop014 0.0616 0.0513 0.0608 0.1178** 0.0191 0.0310 0.0284 0.0669 0.0167 
 (0.0525) (0.0574) (0.0613) (0.0588) (0.0417) (0.0210) (0.0216) (0.0460) (0.0159) 
pop65abv 0.1295** 0.0988* 0.1019** 0.2035*** 0.0151 0.0462** 0.0452** 0.1036* 0.0120 
 (0.0563) (0.0516) (0.0497) (0.0625) (0.0316) (0.0222) (0.0219) (0.0540) (0.0118) 
D.diab_nprev   0.0976*** 0.0076 0.0972**  -0.0166 -0.0457 -0.0281 
   (0.0278) (0.0362) (0.0416)  (0.0184) (0.0300) (0.0223) 
trend 0.0735*** 0.0707*** 0.0733*** 0.0809*** 0.0562*** 0.0495*** 0.0487*** 0.0455*** 0.0516*** 
 (0.0186) (0.0197) (0.0204) (0.0150) (0.0137) (0.0081) (0.0084) (0.0102) (0.0078) 
          
          
# Observations 1254 1255 1255 268 987 1255 1255 268 987 
# Countries 154 155 155 34 121 155 155 34 121 
# Instruments 121 120 130 124 130 120 130 124 130 
Hansen-test 0.113 0.119 0.128 1.000 0.571 0.036 0.079 1.000 0.519 
Diff.-Hansen 0.125 0.089 0.103 1.000 0.459 0.026 0.055 1.000 0.430 
AR(1) 0.037 0.032 0.035 0.201 0.027 0.009 0.009 0.188 0.007 
AR(2) 0.948 0.714 0.676 0.124 0.166 0.517 0.505 0.146 0.132 
          
Notes: See Figure 2 and Table 1. Two-step system-GMM estimations for dynamic panel data models using robust standard errors 
corrected for finite samples (standard errors are reported in parentheses); significance levels at which the null hypothesis is 
rejected: ***, 1%; **, 5%, and *, 10%. The lag of the respective dependent variable, the growth of real GDP per capita (the log of 
rgdppc in the first regression) and the log of sugar and sweeteners availability are treated as endogenous in the GMM estimations; 
the respective lagged values and the other explanatory variables are used as instruments in the first-difference equation and their 
first-differences are used in the levels equation; they were collapsed to avoid the problem of having too many instruments. The 
Hansen-test reports the p-value for the null hypothesis of instrument validity; the difference-in-Hansen test assesses the validity of 
the GMM instruments of the levels equation. The values reported for AR(1) and AR(2) are the p-values of the Arellano-Bond tests 
for first and second order auto-correlated disturbances in the first differences equations. Separate estimations for OECD and Non-
OECD countries are reported, respectively, in columns (4) and (8), and (5) and (9). 
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Table 3. Basic specifications for sugar sensitivity on health care expenditure 
 (1) (2) (3) (4) (5) (6) (7) 
        
L.lnrhcepc 0.9411***       
 (0.0552)       
L2.lnrhcepc -0.2208***       
 (0.0329)       
L.rhcepc_gr  0.1703*** 0.1771*** 0.1754*** 0.1782*** 0.1806*** 0.1758*** 
  (0.0467) (0.0483) (0.0495) (0.0495) (0.0480) (0.0507) 
lnsugar_swt_kcal 0.2568** 21.1031**      
 (0.1146) (9.4556)      
sugar_swt_kcal_gr   0.0798**     
   (0.0346)     
sugar_swt_kcal    0.0926**    
    (0.0383)    
sugar_ptot_kcal     3.1241**   
     (1.2735)   
sugar_ref_kcal      0.0670**  
      (0.0315)  
sugar_swt_gcd       0.2504** 
       (0.1035) 
lnrgdppc 0.1284*       
 (0.0775)       
rgdppc_gr  1.0609*** 0.9569*** 1.0260*** 1.0353*** 1.0502*** 1.0593*** 
  (0.1450) (0.1438) (0.1391) (0.1397) (0.1409) (0.1400) 
pop014 0.0029 1.0866* 0.7067 0.8950** 0.9146** 0.5020* 0.6841** 
 (0.0063) (0.5619) (0.6418) (0.4456) (0.4023) (0.2765) (0.3479) 
pop65abv 0.0292*** 0.7552 0.8074 0.5056 0.9195** 0.3025 0.2993 
 (0.0066) (0.4994) (0.9843) (0.4097) (0.4635) (0.2708) (0.3061) 
trend 0.0067*** 0.8345*** 0.5945*** 0.8129*** 0.9070*** 0.7567*** 0.7426*** 
 (0.0018) (0.1713) (0.0883) (0.1697) (0.1931) (0.1419) (0.1356) 
        
        
# Observations 2212 2224 2222 2224 2224 2224 2222 
# Countries 154 156 156 156 156 156 156 
# Instruments 130 127 126 127 127 127 127 
Hansen-test 0.130 0.298 0.287 0.310 0.263 0.272 0.286 
Diff.-Hansen 0.116 0.251 0.260 0.188 0.238 0.267 0.243 
AR(1) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AR(2) 0.751 0.266 0.284 0.270 0.274 0.293 0.272 
        
Notes: See Table 1. Two-step system-GMM estimations for dynamic panel data models using robust standard errors 
corrected for finite samples (standard errors are reported in parentheses); significance levels at which the null 
hypothesis is rejected: ***, 1%; **, 5%, and *, 10%. The lag of the respective dependent variable, the growth of 
real GDP per capita and the sugar and sweeteners availability are treated as endogenous in the GMM estimations 
(except in regression (1), where logs are used); the respective lagged values and the other explanatory variables are 
used as instruments in the first-difference equation and their first-differences are used in the levels equation; they 
were collapsed to avoid the problem of having too many instruments. The Hansen-test reports the p-value for the 
null hypothesis of instrument validity; the difference-in-Hansen test assesses the validity of the GMM instruments 
of the levels equation. The values reported for AR(1) and AR(2) are the p-values of the Arellano-Bond tests for first 
and second order auto-correlated disturbances in the first differences equations. The dependent variable in 
regression (1) is lnrhcepc, while in the other regressions id rhcepc_gr. 
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Table 4. Baseline specifications for the impact of sugar on health care expenditure 
Sugar variable: Sugar availability in kilocalories Sugar availability as % of total food supply 
 All OECD Non-OECD All OECD Non-OECD 
 (1) (2) (3) (4) (5) (6) 
       
L.rhcepc_gr 0.1653*** 0.3302*** 0.1524*** 0.1699*** 0.3243*** 0.1474*** 
 (0.0531) (0.0631) (0.0520) (0.0522) (0.0614) (0.0522) 
L2.rhcepc_gr  -0.2018***   -0.2000***  
  (0.0441)   (0.0434)  
sugar_swt_kcal 0.0882*** 0.0795** 0.1492***    
 (0.0335) (0.0400) (0.0562)    
sugar_ptot_kcal    2.3027** 2.6260** 4.1526** 
    (1.1127) (1.3157) (1.8900) 
rgdppc_gr 1.1156*** 1.1428*** 1.1850*** 1.1197*** 1.1661*** 1.1211*** 
 (0.1571) (0.2548) (0.1920) (0.1487) (0.2566) (0.1670) 
pop014 0.6968** 3.9109** 0.7309 0.5996** 4.0365** 0.8226* 
 (0.2833) (1.8861) (0.5116) (0.3026) (1.9245) (0.4626) 
pop65abv 0.1391 -0.2851 -0.9707 0.3917 -0.5708 -0.4098 
 (0.3561) (1.8165) (0.8120) (0.3511) (1.9757) (0.5728) 
urban_pop_ptot -0.1196 2.3242*** -0.1910 -0.0723 2.4688*** -0.1653 
 (0.0846) (0.8417) (0.1395) (0.0723) (0.8989) (0.1344) 
lfp_female 0.1505** -0.7489 0.3163** 0.1302* -0.9127* 0.2571* 
 (0.0722) (0.5198) (0.1393) (0.0765) (0.4918) (0.1439) 
hce_pub_texp 0.0452 -0.9421** -0.0496 0.0816 -0.9179** 0.0331 
 (0.0541) (0.4073) (0.1126) (0.0512) (0.4238) (0.0970) 
hosp_beds_gr 0.0445** 0.0233 0.0475** 0.0479** 0.0154 0.0403** 
 (0.0199) (0.1000) (0.0201) (0.0196) (0.0936) (0.0174) 
pollut_pop 0.0799** 0.2162 0.1160* 0.0901** 0.2269 0.1390** 
 (0.0346) (0.1986) (0.0604) (0.0392) (0.1818) (0.0658) 
trend 0.8317*** 0.1093 0.8371*** 0.8703*** 0.1823 1.0225*** 
 (0.1350) (0.5017) (0.2107) (0.1620) (0.5377) (0.2600) 
       
       
# Observations 1987 415 1506 1987 415 1506 
# Countries 151 33 117 151 33 117 
# Instruments 129 73 129 129 73 129 
Hansen-test 0.314 0.999 0.791 0.198 0.999 0.834 
Diff.-Hansen 0.280 0.998 0.703 0.195 0.996 0.725 
AR(1) 0.000 0.000 0.000 0.000 0.000 0.000 
AR(2) 0.290 0.570 0.494 0.299 0.471 0.450 
       
Notes: See Table 1. Two-step system-GMM estimations for dynamic panel data models using robust standard errors 
corrected for finite samples (standard errors are reported in parentheses); significance levels at which the null 
hypothesis is rejected: ***, 1%; **, 5%, and *, 10%. The lag of the dependent variable, the growth of real GDP per 
capita and the sugar and sweeteners availability are treated as endogenous in the GMM estimations; the respective 
lagged values and the other explanatory variables are used as instruments in the first-difference equation and their 
first-differences are used in the levels equation; they were collapsed to avoid the problem of having too many 
instruments. The Hansen-test reports the p-value for the null hypothesis of instrument validity; the difference-in-
Hansen test assesses the validity of the GMM instruments of the levels equation. The values reported for AR(1) and 
AR(2) are the p-values of the Arellano-Bond tests for first and second order auto-correlated disturbances in the first 
differences equations. Separate estimations for OECD and Non-OECD countries are reported, respectively, in 
columns (2) and (5), and (3) and (6). 
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Table 5. Additional variables: diseases and foods 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
L.rhcepc_gr 0.0561 0.1213** 0.1104* 0.1460*** 0.1670*** 0.1654*** 0.1693*** 0.1635*** 0.1650*** 
 (0.0747) (0.0590) (0.0613) (0.0556) (0.0541) (0.0528) (0.0526) (0.0542) (0.0527) 
sugar_swt_kcal 0.0669** 0.0606** 0.0657** 0.0671** 0.0694**   0.0838** 0.0824** 
 (0.0329) (0.0293) (0.0318) (0.0322) (0.0322)   (0.0351) (0.0323) 
sugar_swt_gcd      0.2524*** 0.2429***   
      (0.0936) (0.0894)   
rgdppc_gr 1.1076*** 1.1070*** 0.9526*** 1.0619*** 1.0968*** 1.0708*** 1.0724*** 1.0752*** 1.1112*** 
 (0.1855) (0.1592) (0.1752) (0.1771) (0.1585) (0.1582) (0.1544) (0.1536) (0.1558) 
pop014 -0.0915 0.3775 0.2288 0.4097 0.5672** 0.5783** 0.5504** 0.7815** 0.7016** 
 (0.2353) (0.2822) (0.3528) (0.3359) (0.2738) (0.2485) (0.2374) (0.3459) (0.2852) 
pop65abv 0.2407* 0.0635 0.2561 0.0068 0.1397 0.1381 0.1100 0.3058 0.2248 
 (0.1266) (0.2660) (0.2581) (0.3065) (0.2941) (0.3304) (0.3191) (0.3454) (0.3817) 
urban_pop_ptot 0.0311 -0.0579 -0.0510 -0.0632 -0.0888 -0.1186 -0.1114 -0.1349 -0.1156 
 (0.0612) (0.0628) (0.0622) (0.0768) (0.0729) (0.0801) (0.0752) (0.0834) (0.0822) 
lfp_female 0.0402 0.0774 0.0917 0.0992 0.1155* 0.1136** 0.1047** 0.1779* 0.1330* 
 (0.0521) (0.0562) (0.0995) (0.0656) (0.0662) (0.0561) (0.0531) (0.0977) (0.0701) 
hce_pub_texp 0.0577 0.0567 0.0705 0.0448 0.0502 0.0292 0.0356 0.0509 0.0468 
 (0.0354) (0.0459) (0.0470) (0.0500) (0.0467) (0.0500) (0.0463) (0.0517) (0.0534) 
hosp_beds_gr 0.0365* 0.0450*** 0.0382* 0.0337* 0.0426** 0.0351* 0.0353* 0.0396** 0.0466** 
 (0.0214) (0.0169) (0.0203) (0.0191) (0.0211) (0.0192) (0.0199) (0.0198) (0.0204) 
pollut_pop 0.0276 0.0428* 0.0546** 0.0491* 0.0651** 0.0562** 0.0546** 0.0620** 0.0740** 
 (0.0225) (0.0233) (0.0271) (0.0277) (0.0313) (0.0280) (0.0256) (0.0310) (0.0330) 
trend 0.7558*** 0.4081*** -0.9660*** 0.5042*** 0.8316*** 0.7903*** 0.7832*** 0.8358*** 0.8370*** 
 (0.2601) (0.1463) (0.1924) (0.1448) (0.1346) (0.1285) (0.1264) (0.1360) (0.1341) 
D.diab_nprev -0.4893         
 (0.4127)         
D.obese_prev  -0.4793        
  (0.7743)        
resid_diab   0.3573**       
   (0.1625)       
resid_obese    -0.0030      
    (0.1190)      
D.total_kcal     0.0098     
     (0.0114)     
D.total_fat_gcd      0.4234***    
      (0.1304)    
D.total_prot_gcd      0.1640    
      (0.1856)    
D.anim_prod_fat_gcd       0.2356   
       (0.1988)   
D.oils_gcd       0.1143**   
       (0.0542)   
D.anim_prod_prot_gcd       0.3788   
       (0.2564)   
cereal_kcal        0.0040  
        (0.0045)  
fruit_kcal        0.0107  
        (0.0117)  
vegs_kcal        0.0337  
        (0.0351)  
D.oils_kcal        0.0377***  
        (0.0128)  
D.meat_kcal        0.0534*  
        (0.0285)  
D.fish_kcal        0.0590  
        (0.1032)  
alcohol_kcal         0.0014 
         (0.0151) 
# Observations 1038 1470 1038 1470 1985 1985 1979 1979 1984 
# Countries 150 150 150 150 151 151 150 150 150 
# Instruments 130 130 130 130 130 131 132 135 130 
Hansen-test 0.237 0.549 0.153 0.377 0.236 0.231 0.256 0.307 0.299 
Diff.-Hansen 0.246 0.538 0.164 0.352 0.230 0.191 0.232 0.263 0.251 
AR(1) 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 
AR(2) 0.318 0.164 0.467 0.242 0.324 0.349 0.334 0.334 0.289 
Notes: See Tables 1-4, Table A.3 in Annex and the respective notes. In regressions (6) and (7) we use sugar in grams per capita per day 
for consistency with the unit of measure available for the additional variables for nutrients. 
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Figures 
Figure 1. World sugar and sweeteners food supply (1961-2011), in millions of tonnes 
 
Source: Food and Agriculture Organization of the United Nations (FAOSTAT), Food Supply Database. 
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Figure 2. Sugar and sweeteners food supply/availability, diabetes prevalence, diabetes 
expenditure and total health care expenditure in 2010 
  
  
Notes: See Table 1. 
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ANNEX 
 
Table A.1. Descriptive Statistics 
Variable Obs. Mean Std. Dev. Min. Max. 
rdiab_exp_pc 1987 85.05 653.22 0.01 16524.59 
rdiab_exp_ppd 1987 909.00 1500.99 5.65 10666.51 
rhcepc 3067 894.82 1615.55 8.71 34663.17 
rhcepc_gr 2897 0.40 18.81 -266.05 98.54 
sugar_swt_kcal 3047 279.21 147.23 13.00 664.00 
sugar_ref_kcal 2996 255.14 136.21 4.00 662.00 
sugar_swt_gcd 3045 81.11 43.33 3.26 194.43 
sugar_ptot_kcal 3047 9.98 4.76 0.68 25.36 
sugar_swt_kcal_gr 3044 0.86 10.91 -78.02 84.08 
rgdppc 3836 11093.09 17692.87 69.58 158603.00 
rgdppc_gr 3855 2.54 6.12 -62.21 141.64 
pop014 3880 30.91 10.73 11.76 50.41 
pop65abv 3880 7.28 4.93 0.70 25.71 
urban_pop_ptot 4240 56.09 24.57 7.21 100.00 
lfp_female 3720 56.25 17.37 10.40 90.50 
hce_pub_texp 3543 57.26 20.19 0.33 99.97 
hosp_beds 3014 3.43 2.96 0.10 19.57 
hosp_beds_gr 3001 -1.54 12.21 -184.58 241.29 
pollut_pop 3512 73.11 37.39 0.00 100.00 
diab_nprev 2504 7.29 4.13 0.80 37.90 
obese_prev 2851 16.13 12.32 0.05 81.01 
total_kcal 3047 2713.96 477.10 1571.00 3833.00 
total_fat_gcd 3047 80.09 34.95 13.41 175.46 
total_prot_gcd 3047 76.26 20.47 33.64 138.05 
anim_prod_fat_gcd 3047 36.42 25.05 2.26 110.97 
oils_gcd 3011 57.62 66.02 0.00 515.54 
anim_prod_prot_gcd 3047 34.13 20.26 3.68 101.17 
cereal_kcal 3047 1097.82 327.32 219.00 2231.00 
fruit_kcal 3047 102.86 73.84 4.00 522.00 
vegs_kcal 3047 55.65 37.53 4.00 234.00 
oils_kcal 3013 317.99 152.37 23.00 849.00 
meat_kcal 3047 217.32 149.18 11.00 764.00 
fish_kcal 3045 35.91 38.52 0.00 385.00 
alcohol_kcal 3030 76.88 71.90 0.00 474.00 
unemp_rate 3480 8.86 6.27 0.10 39.30 
surv65_fem 3686 74.32 16.19 14.90 94.72 
surv65_male 3686 65.16 15.22 16.88 90.24 
life_exp_fem 3798 70.80 10.47 35.35 86.70 
life_exp_male 3798 66.00 9.27 28.10 81.80 
pop_dens 4247 376.70 1821.73 0.14 21595.30 
lfp_ratio_fm 3720 68.43 20.00 13.68 108.09 
hce_pub_gdp 3543 3.67 2.35 0.01 21.57 
physicians 3052 1.57 1.43 0.01 7.74 
pollut_expos 3547 17.85 10.44 1.14 75.06 
Notes: See Table 1. Time-period: 1995-2014. 156 countries in the sample (OECD countries in Italic): Afghanistan, 
Albania, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Bahamas, Bangladesh, 
Barbados, Belgium, Belize, Benin, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Bulgaria, 
Burkina Faso, Cape Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Rep. 
Congo, Costa Rica, Cote d'Ivoire, Croatia, Cyprus, Czech Rep., Denmark, Djibouti, Dominican Republic, Ecuador, Egypt, 
Arab Rep., El Salvador, Estonia, Ethiopia, Fiji, Finland, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, 
Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, India, Indonesia, Iran, Islamic 
Rep., Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Rep. Korea, Kuwait, Kyrgyz Rep., Lao 
PDR, Latvia, Lebanon, Lesotho, Liberia, Lithuania, Luxembourg, Macedonia, Madagascar, Malawi, Malaysia, Maldives, 
Mali, Malta, Mauritania, Mauritius, Mexico, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, 
Namibia, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, 
Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Rwanda, Samoa, Sao Tome and Principe, Saudi 
Arabia, Senegal, Serbia, Sierra Leone, Slovak Rep., Slovenia, Solomon Islands, South Africa, Spain, Sri Lanka, St. Lucia, 
St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Sweden, Switzerland, Tanzania, Thailand, Timor-Leste, 
Togo, Trinidad and Tobago, Tunisia, Turkey, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States, 
Uruguay, Vanuatu, Venezuela, Vietnam, and Zambia. 
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Table A.2. Panel unit root tests 
 
IPS test ADF Fisher-type tests 
Variable W t-bar P Z L* Pm 
rdiab_exp_pc -11.44 (0.000) 556.54 (0.000) -6.28 (0.000) -5.87 (0.000) 8.30 (0.000) 
lnrdiab_exp_pc -5.94 (0.000) 637.58 (0.000) -10.85 (0.000) -10.54 (0.000) 11.41 (0.000) 
rdiab_exp_ppd -6.66 (0.000) 672.97 (0.000) -10.77 (0.000) -10.27 (0.000) 12.77 (0.000) 
lnrdiab_exp_ppd -3.77 (0.000) 718.69 (0.000) -13.15 (0.000) -12.72 (0.000) 14.52 (0.000) 
rhcepc -0.27 (0.391) 490.39 (0.000) 2.05 (0.980) 0.23 (0.592) 5.67 (0.000) 
lnrhcepc 1.64 (0.949) 334.43 (0.605) 2.43 (0.993) 2.08 (0.981) -0.29 (614) 
rhcepc_gr -17.08 (0.000) 1090.4 (0.000) -18.98 (0.000) -21.49 (0.000) 28.61 (0.000) 
sugar_swt_kcal -5.81 (0.000) 542.43 (0.000) -4.27 (0.000) -5.30 (0.000) 7.18 (0.000) 
lnsugar_swt_kcal -10.62 (0.000) 662.02 (0.000) -7.96 (0.000) -9.27 (0.000) 11.68 (0.000) 
sugar_ref_kcal -3.44 (0.000) 465.68 (0.000) -3.61 (0.000) -3.80 (0.000) 4.55 (0.000) 
sugar_swt_gcd -10.99 (0.000) 545.94 (0.000) -4.66 (0.000) -5.49 (0.000) 7.31 (0.000) 
sugar_ptot_kcal -6.69 (0.000) 608.85 (0.000) -6.11 (0.000) -7.45 (0.000) 9.68 (0.000) 
sugar_swt_kcal_gr -56.73 (0.000) 4572.9 (0.000) -57.91 (0.000) -95.58 (0.000) 159.08 (0.000) 
rgdppc 16.65 (1.000) 231.26 (1.000) 11.92 (1.000) 12.76 (1.000) -5.79 (1.000) 
lnrgdppc 3.16 (0.999) 491.99 (0.001) 1.88 (0.970) 0.86 (0.805) 3.49 (0.000) 
rgdppc_gr -37.26 (0.000) 2763.7 (0.000) -39.00 (0.000) -52.79 (0.000) 82.47 (0.000) 
pop014 -11.75 (0.000) 1329.5 (0.000) -14.50 (0.000) -20.27 (0.000) 33.80 (0.000) 
pop65abv -2.57 (0.005) 928.11 (0.000) -8.93 (0.000) -11.50 (0.000) 19.38 (0.000) 
urban_pop_ptot -12.30 (0.000) 1080.8 (0.000) -12.80 (0.000) -15.34 (0.000) 22.55 (0.000) 
lfp_female -2.31 (0.010) 583.39 (0.000) -1.86 (0.032) -3.38 (0.000) 7.50 (0.000) 
hce_pub_texp -1.70 (0.045) 480.70 (0.000) -1.74 (0.041) -2.16 (0.016) 3.81 (0.000) 
hosp_beds 7.53 (1.000) 305.14 (0.999) 6.73 (1.000) 6.98 (1.000) -2.78 (0.997) 
hosp_beds_gr -22.87 (0.000) 1920.2 (0.000) -27.23 (0.000) -37.24 (0.000) 55.87 (0.000) 
pollut_pop -3.89 (0.000) 496.86 (0.000) -4.11 (0.000) -4.08 (0.000) 4.85 (0.000) 
D.diab_nprev -7.58 (0.000) 1082.1 (0.000) -12.18 (0.000) -16.63 (0.000) 22.24 (0.000) 
D.obese_prev -12.63 (0.000) 1118.8 (0.000) -17.17 (0.000) -23.69 (0.000) 28.36 (0.000) 
D.total_kcal -49.84 (0.000) 3802.7 (0.000) -51.69 (0.000) -79.35 (0.000) 130.05 (0.000) 
D.total_fat_gcd -53.91 (0.000) 4236.3 (0.000) -55.42 (0.000) -88.43 (0.000) 146.49 (0.000) 
D.total_prot_gcd -51.60 (0.000) 3984.3 (0.000) -53.39 (0.000) -83.10 (0.000) 136.90 (0.000) 
D.anim_prod_fat_gcd -47.23 (0.000) 3516.6 (0.000) -49.30 (0.000) -73.33 (0.000) 119.27 (0.000) 
D.oils_gcd -60.66 (0.000) 4976.3 (0.000) -61.52 (0.000) -104.61 (0.000) 175.44 (0.000) 
D.anim_prod_prot_gcd -40.02 (0.000) 3637.9 (0.000) -49.87 (0.000) -75.84 (0.000) 123.84 (0.000) 
cereal_kcal -3.59 (0.000) 535.94 (0.000) -3.65 (0.000) -4.69 (0.000) 6.93 (0.000) 
fruit_kcal -5.69 (0.000) 651.90 (0.000) -7.04 (0.000) -7.94 (0.000) 8.87 (0.000) 
vegs_kcal -7.47 (0.000) 764.99 (0.000) -8.17 (0.000) -9.36 (0.000) 11.32 (0.000) 
D.oils_kcal -59.07 (0.000) 4778.5 (0.000) -60.08 (0.000) -100.40 (0.000) 167.94 (0.000) 
D.meat_kcal -49.49 (0.000) 3742.8 (0.000) -51.45 (0.000) -78.13 (0.000) 127.80 (0.000) 
D.fish_kcal -54.73 (0.000) 4665.0 (0.000) -58.83 (0.000) -98.00 (0.000) 162.55 (0.000) 
alcohol_kcal -1.73 (0.042) 502.41 (0.000) -2.72 (0.003) -3.29 (0.001) 5.76 (0.000) 
unemp_rate -5.49 (0.000) 614.92 (0.000) -7.69 (0.000) -8.35 (0.000) 10.12 (0.000) 
surv65_fem -3.27 (0.001) 628.46 (0.000) -3.72 (0.000) -4.49 (0.000) 8.63 (0.000) 
surv65_male -9.30 (0.000) 696.69 (0.000) -9.76 (0.000) -10.07 (0.000) 11.08 (0.000) 
life_exp_fem -4.43 (0.000) 1389.2 (0.000) -5.20 (0.000) -14.95 (0.000) 34.81 (0.000) 
life_exp_male -3.21 (0.001) 1288.1 (0.000) -4.56 (0.000) -11.29 (0.000) 31.24 (0.000) 
pop_dens -13.98 (0.000) 2052.0 (0.000) -17.40 (0.000) -31.80 (0.000) 55.70 (0.000) 
lfp_ratio_fm -2.71 (0.003) 536.31 (0.000) -2.79 (0.003) -3.58 (0.000) 6.02 (0.000) 
hce_pub_gdp -3.17 (0.001) 578.77 (0.000) -3.42 (0.000) -4.58 (0.000) 7.39 (0.000) 
physicians -2.75 (0.003) 557.16 (0.000) -3.03 (0.001) -3.38 (0.000) 5.47 (0.000) 
pollut_expos -4.85 (0.000) 552.45 (0.000) -5.47 (0.000) -5.66 (0.000) 6.89 (0.000) 
Notes: See Tables D1 and D2. IPS stands for the Im-Pesaran-Shin panel unit root test; the W t-bar statistic is 
reported followed by the respective p-value in parentheses. Four Fisher-type ADF unit-root test statistics are also 
reported (the respective p-values are in parentheses): inverse chi-squared P; inverse normal Z; inverse logit L*; and 
the modified inverse chi-squared Pm. One lag of the series is used in the ADF regressions, but different lag 
structures produce similar results. Phillips-Perron unit-root tests were also considered, but the conclusions remain 
unchanged (those results are not reported here but are available upon request). These tests are preferred due to the 
fact of the panel is not strongly balanced. “D.” stands for the first-difference of the respective variable. 
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Table A.3. Sensitivity analysis: diabetes expenditure 
Dep. Variable: lnrdiab_exp_pc lnrdiab_exp_ppd 
 (1) (2) (3) (4) (5) (6) 
       
L.lnrdiab_exp_pc 0.4751*** 0.4811*** 0.4785***    
 (0.1484) (0.1590) (0.1667)    
L.lnrdiab_exp_ppd    0.7991*** 0.8094*** 0.8019*** 
    (0.1103) (0.1110) (0.1031) 
lnsugar_swt_kcal 1.9507** 2.9909** 3.3141** 0.5778** 0.7685** 0.9585** 
 (0.7583) (1.2268) (1.3501) (0.2351) (0.3714) (0.4147) 
rgdppc_gr 0.0150** 0.0141** 0.0138* -0.0001 0.0013 0.0003 
 (0.0064) (0.0071) (0.0079) (0.0041) (0.0045) (0.0043) 
pop014 0.0337 0.0965 0.0961 0.0166 0.0226 0.0390* 
 (0.0478) (0.0699) (0.0759) (0.0140) (0.0205) (0.0215) 
pop65abv 0.0841** 0.1268** 0.1128 0.0383*** 0.0396* 0.0525** 
 (0.0394) (0.0563) (0.0702) (0.0146) (0.0225) (0.0245) 
D.obese_prev 0.1591   0.0530   
 (0.1452)   (0.0445)   
resid_diab  0.0831**   0.0390  
  (0.0411)   (0.0250)  
resid_obese   -0.0327   0.0068 
   (0.0419)   (0.0194) 
trend 0.0587*** 0.0664** 0.1006*** 0.0438*** 0.0560*** 0.0500*** 
 (0.0130) (0.0272) (0.0336) (0.0069) (0.0091) (0.0121) 
       
       
# Observations 1255 1255 1255 1255 1255 1255 
# Countries 154 155 155 154 155 155 
# Instruments 130 130 130 130 130 130 
Hansen test 0.6915 0.1025 0.8027 0.6820 0.0894 0.6947 
Diff.-Hansen  0.0751 0.7483  0.0639 0.6181 
AR(1) 0.0318 0.0338 0.0316 0.0087 0.0080 0.0085 
AR(2) 0.6802 0.7310 0.9261 0.4822 0.5207 0.5328 
       
Notes: See Table 2. The variables resid_diab and resid_obese are the residuals of the estimation of, 
respectively, diabetes prevalence and obesity prevalence on sugar intake. Hence, these represent the part of 
diabetes prevalence and obesity prevalence that is not explained by sugar intake. 
 
 
  
 40 
 
 
Table A.4. Sensitivity analysis: total health care expenditure 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
          
L.rhcepc_gr 0.2145*** 0.1653*** 0.1654*** 0.1669*** 0.1660*** 0.1660*** 0.1824*** 0.1631*** 0.1374*** 
 (0.0403) (0.0508) (0.0511) (0.0530) (0.0529) (0.0523) (0.0522) (0.0532) (0.0530) 
sugar_swt_kcal 0.1246*** 0.1015*** 0.0994*** 0.0878** 0.0846*** 0.0862*** 0.0634** 0.1044*** 0.0424** 
 (0.0425) (0.0346) (0.0340) (0.0346) (0.0322) (0.0295) (0.0303) (0.0380) (0.0210) 
rgdppc_gr  1.1312*** 1.1274*** 1.1032*** 1.1105*** 1.1377*** 1.2417*** 1.1074*** 0.9517*** 
  (0.1585) (0.1571) (0.1562) (0.1565) (0.1618) (0.1567) (0.1571) (0.1668) 
pop014 0.5609   0.7830** 0.6643** 0.6219** 0.4476* 0.7850** 0.3872* 
 (0.4328)   (0.3146) (0.2683) (0.2815) (0.2605) (0.3054) (0.2237) 
pop65abv -0.0625   0.0680 0.1164 -0.1530 0.1670 0.3724 0.1220 
 (0.7484)   (0.3765) (0.3426) (0.4657) (0.3175) (0.3790) (0.2346) 
urban_pop_ptot -0.3272** -0.1721* -0.1437  -0.1138 -0.1353* -0.1076 -0.1501 -0.0536 
 (0.1343) (0.0945) (0.0878)  (0.0787) (0.0778) (0.0863) (0.0922) (0.0577) 
lfp_female 0.1304 0.0803 0.1025* 0.1844**  0.1452** 0.0896 0.2223** 0.0530 
 (0.1540) (0.0612) (0.0619) (0.0893)  (0.0663) (0.0590) (0.0976) (0.0529) 
hce_pub_texp 0.0258 0.0040 0.0089 0.0218 0.0470  0.0754 0.0212 0.0622 
 (0.0800) (0.0643) (0.0619) (0.0594) (0.0513)  (0.0473) (0.0589) (0.0388) 
hosp_beds_gr 0.0299 0.0481** 0.0474** 0.0440** 0.0452** 0.0440**  0.0451* 0.0353 
 (0.0190) (0.0190) (0.0191) (0.0193) (0.0196) (0.0202)  (0.0232) (0.0237) 
pollut_pop 0.1011* 0.0561* 0.0484* 0.0879** 0.0751** 0.0845*** 0.0579*  0.0506** 
 (0.0565) (0.0291) (0.0269) (0.0378) (0.0327) (0.0308) (0.0322)  (0.0243) 
trend 0.7487*** 0.7508*** 0.7643*** 0.8273*** 0.8156*** 0.7823*** 0.8625*** 0.8510***  
 (0.1767) (0.1282) (0.1278) (0.1371) (0.1291) (0.1479) (0.1546) (0.1418)  
unemp_rate -1.1661*         
 (0.6466)         
surv65_fem  -0.7499***        
  (0.2471)        
surv65_male  0.3808**        
  (0.1825)        
life_exp_fem   -1.5234***       
   (0.5665)       
life_exp_male   0.9905*       
   (0.5074)       
pop_dens    -0.0029      
    (0.0051)      
lfp_ratio_fm     0.1377**     
     (0.0686)     
hce_pub_gdp      1.1033    
      (0.7253)    
physicians       -0.4458   
       (0.8972)   
pollut_expos        0.4123**  
        (0.1819)  
          
          
# Observations 1922 1987 1987 1984 1987 1987 1980 1987 1987 
# Countries 145 151 151 151 151 151 151 151 151 
# Instruments 99 129 129 129 129 129 132 129 143 
Hansen-test 0.121 0.381 0.387 0.287 0.312 0.319 0.287 0.349 0.344 
Diff.-Hansen 0.084 0.332 0.341 0.267 0.278 0.295 0.288 0.305 0.291 
AR(1) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AR(2) 0.276 0.284 0.282 0.302 0.290 0.277 0.308 0.281 0.277 
          
Notes: See Tables 1, 4 and 5, and the respective notes. In regression (9) the trend is replaced by time dummies. 
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Table A.5. Robustness checks: lags of sugar and estimators 
 Lags of the sugar variable Alternative estimators 
 Lag 1 Lag 2 Lag3  Lag 4 Lag 5 Diff.GMM FE 
 (1) (2) (3) (4) (5) (6) (7) 
        
L.rhcepc_gr 0.1685*** 0.1683*** 0.1706*** 0.1702*** 0.1757*** 0.1586*** 0.1186*** 
 (0.0539) (0.0530) (0.0529) (0.0530) (0.0532) (0.0511) (0.0408) 
L.sugar_swt_kcal 0.0685**       
 (0.0343)       
L2.sugar_swt_kcal  0.0505*      
  (0.0281)      
L3.sugar_swt_kcal   0.0281     
   (0.0243)     
L4.sugar_swt_kcal    0.0483**    
    (0.0247)    
L5.sugar_swt_kcal     -0.0176   
     (0.0234)   
sugar_swt_kcal      0.1547*** 0.0356** 
      (0.0413) (0.0140) 
rgdppc_gr 1.1476*** 1.1622*** 1.1577*** 1.1639*** 1.1161*** 1.3038*** 1.5932*** 
 (0.1511) (0.1458) (0.1472) (0.1496) (0.1504) (0.2052) (0.3122) 
pop014 0.5534** 0.4292* 0.2598 0.3831* -0.0596 -0.2765 0.1024 
 (0.2796) (0.2338) (0.1850) (0.2043) (0.1700) (0.6778) (0.3174) 
pop65abv 0.1007 0.0832 0.0587 0.0370 0.0411 0.9262** 0.9231 
 (0.2753) (0.2436) (0.1621) (0.2669) (0.1143) (0.4658) (0.8487) 
urban_pop_ptot -0.1013 -0.0686 -0.0298 -0.0730 0.0526 0.0026 0.2837 
 (0.0819) (0.0671) (0.0541) (0.0639) (0.0444) (0.4326) (0.2542) 
lfp_female 0.1337* 0.0859 0.0524 0.0898* -0.0246 0.1539 0.1860 
 (0.0774) (0.0577) (0.0476) (0.0514) (0.0467) (0.1603) (0.1497) 
hce_pub_texp 0.0708 0.0781* 0.0831** 0.0748* 0.0948*** 0.0429 0.0472 
 (0.0477) (0.0422) (0.0330) (0.0451) (0.0319) (0.0941) (0.1055) 
hosp_beds_gr 0.0426** 0.0393** 0.0365* 0.0373** 0.0412** 0.0455* 0.0357* 
 (0.0193) (0.0193) (0.0189) (0.0177) (0.0206) (0.0251) (0.0199) 
pollut_pop 0.0665** 0.0543** 0.0381* 0.0535** 0.0035 0.1956 0.1975** 
 (0.0305) (0.0249) (0.0214) (0.0264) (0.0204) (0.1624) (0.0806) 
trend 0.8063*** 0.7372*** 0.7123*** 0.7244*** 0.6665*** 0.6465** 0.6734*** 
 (0.1359) (0.1239) (0.1056) (0.1097) (0.1055) (0.3293) (0.1851) 
        
        
# Observations 2024 2022 2019 2016 2012 1836 1987 
# Countries 151 151 151 150 150 150 151 
# Instruments 128 127 126 125 125 125  
R2       0.089 
Hansen-test 0.140 0.141 0.136 0.155 0.179 0.312  
Diff.-Hansen 0.120 0.110 0.107 0.130 0.140   
AR(1) 0.000 0.000 0.000 0.000 0.000 0.000  
AR(2) 0.319 0.301 0.349 0.320 0.336 0.247  
        
Notes: See Table 1, 4 and 5, and the respective notes. A system-GMM estimator is used in regressions (1)-(5). In 
column (6) are shown the results from a difference-GMM estimator, while a fixed-effects estimator was used to 
obtain the results reported in column (7); robust standard errors are reported in parentheses. 
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Table A.6. Robustness checks: regional areas 
 OECD Non-OECD Europe Africa Asia NorthAm. SouthAm. Oceania 
 (1) (2) (3) (4) (5) (6) (7) (8) 
         
L.rhcepc_gr 0.3054*** 0.0853* 0.2773***  0.1185*  0.1699*  
 (0.0443) (0.0443) (0.0424)  (0.0592)  (0.0857)  
sugar_swt_kcal 0.0312* 0.0428** 0.0328* 0.1114** 0.0008 0.0486** 0.0144 0.0183 
 (0.0184) (0.0186) (0.0187) (0.0546) (0.0256) (0.0235) (0.0572) (0.0349) 
rgdppc_gr 1.2256*** 1.3430*** 1.5999*** 0.7315** 1.1177*** 0.5306*** 2.8369*** 0.0614 
 (0.2870) (0.2091) (0.2367) (0.3051) (0.3428) (0.1667) (0.6581) (0.8544) 
pop014 2.1643** 0.2217 1.4253* 1.8778* 0.0238 -0.9166 1.2987 -5.2497 
 (1.0586) (0.3678) (0.8400) (0.9988) (0.8588) (0.6559) (2.3348) (2.7649) 
pop65abv 0.2027 2.1307 1.0048 4.8607 1.4529 -2.2534 9.3401 12.8896* 
 (0.8527) (1.2932) (1.2009) (4.7260) (2.2278) (1.3564) (5.7887) (5.3148) 
urban_pop_ptot 0.5638 0.3239 0.4308 1.3642 -0.0569 0.9027*** -6.3945*** 0.1122 
 (0.5036) (0.2663) (0.5728) (0.9648) (0.7626) (0.2195) (1.4271) (2.8890) 
lfp_female 0.0716 -0.1859 -0.3184 -0.0290 -0.6964 0.4756* 1.2379 1.7370** 
 (0.3126) (0.2648) (0.3252) (0.6678) (0.7180) (0.2510) (1.1205) (0.5552) 
hce_pub_texp -0.2648* 0.0129 -0.4268* -0.0881 0.0122 -0.4297*** -0.0564 1.3651** 
 (0.1565) (0.0974) (0.2353) (0.2549) (0.1026) (0.1174) (0.3643) (0.3813) 
hosp_beds_gr 0.0280 0.0070 -0.1747 0.0052 0.0242 -0.0370 -0.0192 -0.0366 
 (0.0746) (0.0208) (0.2200) (0.0395) (0.0371) (0.0402) (0.0450) (0.1666) 
pollut_pop 0.0457 0.1501 0.0232 0.3723*** 0.0170 -0.0682 0.4897** -0.1928 
 (0.0894) (0.0973) (0.1116) (0.1375) (0.1961) (0.0708) (0.2233) (0.2593) 
trend 0.0990 0.6370*** 0.6068 0.8339* 0.9979** -0.4204 1.0187 -0.2846 
 (0.3646) (0.2102) (0.3691) (0.4631) (0.4749) (0.2641) (0.8954) (0.5911) 
         
         
# Observations 481 1506 559 551 425 282 164 84 
# Countries 34 117 40 42 33 17 13 6 
R2 0.286 0.167 0.304 0.0933 0.1705 0.1270 0.4231 0.1258 
         
Notes: See Table 1, 4, and 5, and the respective notes. A fixed-effects estimator was used to obtain the results 
reported in this table. Robust standard errors are reported in parentheses. 
 
 
